drugset / Trial / NCT04679948

A Study in Healthy People to Test Whether BI 730357 Influences the Amount of Caffeine, Warfarin, Omeprazole, and Midazolam in the Blood

NCT04679948

Phase 1 Completed 16 enrolled Boehringer Ingelheim
NaSingle-groupOpen-labelTreatment

Summary

The trial will be performed to assess the influence of BI 730357 on the pharmacokinetics of caffeine, warfarin, omeprazole and midazolam.

Timeline

Start
2020-12-21
Primary completion
2021-03-17
Completion
2021-03-17

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 730357 Unknown
Subject Caffeine Small molecule Oral
Subject Midazolam Small molecule Oral
Subject Omeprazole Other / unclassified Oral
Subject Warfarin Small molecule Oral

Indications

No indication recorded.